Welcome to the John Carroll University Student Health Center!

We require a completed student health form for <u>all</u> students before classes begin.

- 1. Return the completed form to John Carroll University, (for fall semester no later than August 1, spring semester no later than January 1) to the address below, email from your JCU account to ikrevh@icu.edu, or fax to the number below.
- 2. Include a copy of your medical insurance card -- both sides.
- 3. We strongly recommend that you be immunized against bacterial meningitis by receiving a meningitis vaccine.
- 4. If you have a condition requiring continuing care (e.g. diabetes, hypertension, emotional disorders, seizures), please have your physician send a letter with his/her suggestions for necessary follow-up, medications, etc.
- 5. No physical exam is required.
- 6. **Information for varsity athletes:** All varsity athletes are required to have a physical examination by John Carroll's sports medicine team physician prior to the first scheduled practice. Please check **www.jcusports.com** for additional information pertaining to when physicals are scheduled and insurance information. If you have additional questions, please don't hesitate to e-mail or call Don McPhillips M.S., ATC, LAT, head athletic trainer at dmcphillips@jcu.edu or 216.397.4503.
- 7. If you are under the age of 18, you must have your parent or guardian must fill out this form and sign on page 3.

Student Health Center
1 John Carroll Boulevard
University Heights, OH 44118-4581
Telephone: 216.397.4349 ◆ fax: 216.397.1787

Email: jkrevh@jcu.edu

TO: Student Health Center
John Carroll University
1 John Carroll Boulevard
University Heights, OH 44118
(F) 216.397.1787

Signature



Student Health Record THIS IS A CONFIDENTIAL COMMUNICATION

Date of Birth/
Relationship State Zip Cell Ph () pe of reaction:
Relationship State Zip Cell Ph () pe of reaction:
State Zip Cell Ph () pe of reaction:
Dell Ph ()
Dell Ph ()
pe of reaction:
cluding birth control pills:
in school, please indicate: [] yes
Date of Birth// Business Phone () Group Number
ment below if necessary) S NO [] Asthma or Wheezing w/Bronchitis] [] Hepatitis or Jaundice] [] Seizures or Convulsions] [] High Blood Pressure] [] HIV Infection] [] Tuberculosis] [] Anxiety/Panic Attacks] [] Depression/Mood Disorders] [] Alcohol/Drug Abuse] [] Anorexia/Bulimia] [] Migraine Headaches] [] Schizophrenia Tobacco Use:] [] smoke] [] Other
Date
]

supervision. I further understand and agree a photocopy of this signed consent will have the same force and validity as the or iginal.)

Date

Meningococcal and Hepatitis B Vaccination Status Form

Name of Student:	Date of Birth://
I, the undersigned student (if 18 years of age or older) of understand the information provided to me about Meni understand the benefits and risks of being vaccinated ago The information below regarding my/my student's vacci in compliance with the Ohio Revised Code, Section 3701	ingococcal Meningitis and Hepatitis B. I gainst these diseases. ination status is accurate and is being provided
Meningococcal vaccine(MCV4) received at age 16 or old First dose date:// Second	er: Yes No dose date://
Hepatitis B vaccine received: Yes No If yes, please list the dates: 1st Dose//2	 2nd Dose / / 3rd Dose / /
Signature (If student under 18 years of age, please have parent s	

Part I

Nama			
First Name	Middle Name		Last Name
Address		City	Stato 7in
	f Birth//	City	State Zip
PART II			
A. M.M.R. (MEASLES, MUMP) (Two doses required at least 28 days 1. Dose 1 given at age 12 months or	apart for students born after 1		
2. Dose 2 given at least 28 days after	first dose	#2	M D Y
B. POLIO (Primary series, doses at least 28 day 1. OPV alone (oral Sabin three doses 2. IPV/OPV sequential: IPV #1 //): #1// #2//	#3//	
IPV/OPV sequential: IPV #1/_ M IPV alone (injected Salk four doses)	S): #1// #2/ #2/	M D Y M M M M M M M M M M M M M M M M M	<u></u>
C. VARICELLA (Birth in the U.S. before 1980, a histor) 1. History of Disease Yes	ory of chicken pox, a positive va No or Birth in U.S. befor Result: Reactive #1_ fter first dose ages 1-12 years #	aricella antibody, or two doses on the 1980 Yes No Non-reactive	
should receive one dose of Tdap at a 1. Primary series of four doses with I #1// #2// #3	or Td, and booster with Td or T in interval as short as 2 years si DTaP, DTP, DT, or Td:	nce last Td as appropriate. Refe ter immunization at least 2-5 ye	ars since last dose of Td, depending on
3. Booster: Td within the last ten year	ırs		J/
E. QUADRIVALENT HUMAN P (Three doses of vaccine for female of Immunization (HPV) a. Dose #1// b. Dose #2 _	ollege students 11-26 years of a	age at 0, 2, and 6 month interva	als.)

F. HEPATITIS A

1. Immunization (hepatitis A)

2. Immunization (Combined hepatitis A and B vaccine)

a. Dose #1 ___/__ b. Dose #2 ___/__/ c. Dose #3 __/__/ ___/

G. HEPATITIS B

(All college and health sciences students. Three doses of vaccine or two doses of adult vaccine in adolescents 11-15 years of age, or a positive hepatitis B surface antibody meets the requirement.)

1. Immunization (hepatitis B)

a. Dose #1 ___/___ b. Dose #2 ___/___ c. Dose #3 ___/___ Y

Adult formulation Child formulation

2. Immunization (Combined hepatitis A and B vaccine)

a. Dose #1 ___/__/__ b. Dose #2 ___/__/_ c. Dose #3 ___/__/__ M _ D _ Y c. Dose #3 ___/__/__ 3. Hepatitis B surface antibody Date ___/__/__

Result: Reactive

H. MENINGOCOCCAL TETRAVALENT

(A,C,Y,W-135 / One dose — for college freshmen living in dormitories/residence halls, persons with terminal complement deficiencies or asplenia, laboratory personnel with exposure to aerosolized meningococci, and travelers to hyperendemic or endemic areas of the world.

Non-freshmen college students may choose to be vaccinated to reduce their risk of meanings.

Tetravalent conjugate (preferred; data for revaccination pending; administer simultaneously with Tdap if possible): Date ___/__/___

M D Y

I. TUBERCULOSIS (TB) SCREENING/TESTING

Have you ever had a positive TB skin test? Yes

Have you ever had close contact with anyone who was sick with TB?

Yes

No

Were you born in one of the countries listed below and arrived in the U.S. within the past 5 years? Yes No

Papua New Guinea

Russian Federation

Paraguay

Peru Philippines

Poland

Qatar

Portugal

Romania

Rwanda

St. Vincent &

Saudi Arabia

Senegal

Seychelles

Singapore

Somalia

Spain

Sudan

Sri Lanka

Suriname

Syrian Arab Republic

Wallis & Futuna Islands W. Bank & Gaza Strip

Yemen

Sierra Leone

South Africa

Solomon Islands

The Grenadines

Sao Tome & Principe

No

(If yes, please circle the country)

Have you ever traveled** to/in one or more of the countries listed below? Yes No

(If yes, please check the country/ies)

Have you ever been vaccinated with BCG? Yes No

Afghanistan Guinea Algeria Guinea-Bissau Angola Guyana Anguilla Haiti Argentina Honduras Armenia India Azerbaijan Indonesia Bahamas Iran Bahrain Iraq Bangladesh Japan Belarus Kazakhstan Belize Kenya Benin Kiribati Korea-DPR Bhutan Bolivia Korea-Republic Bosnia & Herzegovina Kuwait Botswana Kyrgyzstan Brazil Lao PDR Brunei Darussalam Latvia Lesotho Bulgaria **Burkina Faso** Liberia Burundi Lithuania Cambodia Macedonia-TFYR Cameroon Madagascar Cape Verde Malawi Central African Rep. Malaysia

Maldives Chad Swaziland China Mali Tajikistan Colombia Marshall Islands Tanzania-UR Comoros Mauritania Thailand Mauritius Congo Timor-Leste Mexico Congo DR Togo Cote d'Ivoire Micronesia Tokelau Croatia Moldova-Rep. Tonga Djibouti Mongolia Tunisia **Dominican Republic** Montenegro Turkey Ecuador Morocco Turkmenistan Mozambique Tuvalu Egypt El Salvador Myanmar Uganda **Equatorial Guinea** Namibia Ukraine Eritrea Nauru Uruguay Estonia Uzbekistan Nepal Ethiopia New Caledonia Vanuatu Venezuela Fiji Nicaragua French Polynesia Niger Viet Nam

Ghana Pakistan Zambia
Guam Palau Zimbabwe
Guatemala Panama

N. Mariana Islands

Nigeria

Niue

If the answer is **YES** to any of the above questions, John Carroll University requires that a health care provider complete a tuberculosis risk assessment (to be completed prior to the start of classes).

If the answer to all of the above questions is **NO**, no further testing or further action is required and the questions on pages 7-8 can be disregarded.

Gabon

Gambia Georgia

J. TUBERCULOSIS (TB) RISK ASSESSMENT

Persons with any of the following risk factors are candidates for either Mantoux tuberculin skin test (TST) or Interferon Gamma Release Assay (IGRA), unless a previous positive test has been documented:

Recent close conta	act with someone with infectious TB disease
Yes	No
Foreign-born from Yes	(or travel* to/in) a high-prevalence area (e.g., Africa, Asia, Eastern Europe, or Central or South America) No
Fibrotic changes of Yes	n a prior chest x-ray suggesting inactive or past TB disease No
HIV/AIDS Yes	No
Organ transplant r Yes	ecipient No
Immunosuppresse Yes	d (equivalent of > 15 mg/day of prednisone for >1 month or TNF- α antagonist) No
History of illicit dru Yes	ug use No
	e, or volunteer in a high-risk congregate setting (e.g., correctional facilities, nursing homes, homeless shelters, er health care facilities) No
lung cancer, hema	associated with increased risk of progressing to TB disease if infected [e.g., diabetes mellitus, silicosis, head, neck, or tologic or reticuloendothelial disease such as Hodgkin's disease or leukemia, end stage renal disease, intestinal bypass pronic malabsorption syndrome, low body weight (i.e., 10% or more below ideal for the given population)] No
If No, proceed to 2 testing, chest x-ray 2. Tuberculin Skin (TST result should The TST interpreta Date Given:/	be recorded as actual millimeters (mm) of induration, transverse diameter; if no induration, write "0". tion should be based on mm of induration as well as risk factors.)** / Date Read:// D Y
Date Given:/ M Result: r 3. Interferon Gamr Date Obtained:	mm of induration **Interpretation: Positive Negative / Date Read://
Result: Positive Date Obtained: Result: Positive 4. Chest x-ray: (Ree	Negative Intermediate //(specify method) QFT-G QFT-GIT other

>5 mm is positive:

- Recent close contacts of an individual with infectious TB
- Persons with fibrotic changes on a prior chest x-ray consistent with past TB disease
- Organ transplant recipients
- Immunosuppressed persons: taking > 15 mg/d of prednisone for > 1 month; taking a TNF- α antagonist
- Persons with HIV/AIDS

>10 mm is positive:

- Persons born in a high prevalence country or who resided in one for a significant* amount of time
- History of illicit drug use
- Mycobacteriology laboratory personnel
- History of resident, worker or volunteer in high-risk congregate settings
- Persons with the following clinical conditions: silicosis, diabetes mellitus, chronic renal failure, leukemias and lymphomas, head, neck or lung cancer, low body weight (>10% below ideal), gastrectomy or intestinal bypass, chronic malabsorption syndromes

>15 mm is positive:

• Persons with no known risk factors for TB disease

HEALTH CARE PROVIDER	
Name	Address
Signature	Phone

MENINGOCOCCAL DISEASE AND COLLEGE STUDENTS

Meningococcal disease is a serious illness caused by bacteria. It is the leading cause of bacterial meningitis in children 2-18 years of age in the United States. Meningococcal bacteria can cause meningitis (inflammation of the lining of the brain and spinal cord) or sepsis (an infection of the bloodstream). Symptoms of meningitis include stiff neck, headache, fever, nausea, vomiting, confusion, and drowsiness. Symptoms of sepsis include fever, shock, and coma. Death from sepsis can occur within 12 hours of the beginning of the illness – meningococcal disease can be a rapid and overwhelming infectious disease. For these reasons, meningococcal infections that occur in childcare centers, elementary schools, high schools, and colleges often cause panic in the community. Every year about 2,600 people in the United States are infected with meningococcus. Ten to 15 percent of these people die in spite of treatment with antibiotics. Of those who live, another 10 percent lose their arms or legs, become deaf, have problems with their nervous systems, become mentally retarded or suffer seizures or strokes.

How do you catch meningococcal infection?

Usually meningococcal infection is acquired after intimate contact with an infected person. Intimate contact includes kissing, sharing toothbrushes or eating utensils, or frequently eating or sleeping in the same dwelling as an infected individual.

Who is at risk?

Anyone can get meningococcal disease, but it is most common in infants less than 1 year of age and in people with certain medical conditions. College freshmen, particularly those who live in dormitories, have a slightly increased risk of getting meningococcal disease. The risk for meningococcal disease among nonfreshmen college students is similar to that for the general population; however, the vaccine is safe and effective and therefore can be provided to nonfreshmen undergraduates who want to reduce their risk for meningococcal disease.

What can be done to decrease risk?

The meningococcal vaccine can prevent four types of meningococcal disease. These include two of the three most common types in the United States. Meningococcal vaccine cannot prevent all types of the disease, but it does help to protect people who might become sick if they don't get the vaccine. The vaccine is available through a variety of settings including physician offices and university/college student health centers.

What about the vaccine?

A vaccine, like any other medicine, is capable of causing serious problems, such as allergic reactions. People should not get meningococcal vaccine if they have ever had a serious allergic reaction to a previous dose of the vaccine. Some people who get the vaccine may develop redness or pain where the shot was given, and a small percentage of people develop a fever. These symptoms usually last for one or two days. The risk of the meningococcal vaccine causing serious harm is extremely small. Getting meningococcal vaccine is safer than getting the disease. People who are mildly ill at the time the shot is scheduled, and women who are pregnant, can still get the vaccine. Those with moderate or severe illnesses should usually wait until they recover. College students and their parents should discuss the timing, risks, and benefits of vaccination with their health care providers. For more information about the meningococcal vaccine, access the Vaccine Information Sheet at the Centers for Disease Control and Prevention (CDC) web site http://www.cdc.gov/nip/publications/VIS. If college students decide to be vaccinated against meningococcal meningitis, they (or their parents if they are less than 18 years of age) should contact their health care provider or the university/college student health center where they will be attending to inquire about receiving the vaccine.

Adapted from CDC and the Children's Hospital of Philadelphia Vaccine Education Center publications.

HEPATITIS B AND COLLEGE STUDENTS

Hepatitis B is a serious disease. Hepatitis B is a virus that affects the liver. It is one of several hepatitis diseases (for example, hepatitis A and hepatitis C) that are caused by different viruses but are similar in that they all attack the liver. The hepatitis B virus (HBV) can cause a short-term (acute) illness that leads to loss of appetite, stomach pain, tiredness, diarrhea, vomiting, jaundice (yellow skin or eyes), and pain in muscles and joints. These symptoms can last for several weeks. It can also cause a long-term (chronic) illness from which people never recover. A person might not look or feel sick, but he or she carries the hepatitis B virus in their blood for the rest of their lives and can infect other people with the hepatitis B virus. Chronic hepatitis B may cause liver damage (cirrhosis), liver cancer, and even death. About 1.25 million people in the United States have chronic HBV infection. Each year 80,000 more people, **mostly young adults**, get infected with HBV and 4,000 to 5,000 people die from chronic hepatitis B.

How do you catch hepatitis B?

Hepatitis B virus is spread through contact with blood or other body fluids of an infected person. You can catch the virus by having unprotected sex, by sharing drug needles or by sharing personal items like razors and toothbrushes with someone who is infected. Babies of chronic HBV mothers can become infected during birth. Children can be infected through exposure to blood and other body fluids from infected children or adults.

Who is at risk?

Anyone who participates in any of the behaviors listed above is at risk of acquiring hepatitis B.

What can be done?

There are hepatitis B vaccines available that can prevent infection from the virus. Many physicians offer the vaccine to patients seen in their offices. These are the first anti-cancer vaccines, because they can prevent a form of liver cancer that can develop in a person who gets a chronic hepatitis B infection.

What about the vaccine?

A vaccine, like any medicine, is capable of causing serious problems, such as allergic reactions. Most people who get the hepatitis B vaccine do not have any problems with it. People who have ever had a life-threatening allergic reaction to baker's yeast (the kind used to make bread) or to a previous dose of hepatitis B vaccine should not get the vaccine. People who are moderately to severely ill at the time the shot is scheduled should usually wait until they recover before getting the vaccine. Hepatitis B vaccine is very safe and the risk of it causing serious harm is extremely small. Hepatitis is a serious disease and getting the vaccine is safer than getting the disease. College students and their parents should discuss the risks and the benefits of vaccination with their health care providers. For more information about the hepatitis vaccine, access the Vaccine Information Sheet at the Center for Disease Control and Prevention (CDC) website http://www.cdc.gov/nip/publications/VIS. If college students decide to be vaccinated against hepatitis B, they (or their parents if they are less than 18 years of age) should contact their health care provider or the university/college student health center where they will be attending to inquire about receiving the vaccine.

Adapted from CDC publications.